Dyne Therapeutics Inc (DYN)
24.87
+1.01
(+4.23%)
USD |
NASDAQ |
Apr 22, 16:00
24.86
-0.01
(-0.04%)
Pre-Market: 20:00
Dyne Therapeutics Research and Development Expense (Quarterly): 58.84M for Dec. 31, 2023
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 58.84M |
| September 30, 2023 | 55.25M |
| June 30, 2023 | 59.13M |
| March 31, 2023 | 37.54M |
| December 31, 2022 | 33.19M |
| September 30, 2022 | 34.67M |
| June 30, 2022 | 46.66M |
| March 31, 2022 | 28.24M |
| December 31, 2021 | 42.30M |
| Date | Value |
|---|---|
| September 30, 2021 | 36.51M |
| June 30, 2021 | 23.87M |
| March 31, 2021 | 18.62M |
| December 31, 2020 | 22.10M |
| September 30, 2020 | 9.679M |
| June 30, 2020 | 7.334M |
| March 31, 2020 | 6.089M |
| December 31, 2019 | 4.259M |
| September 30, 2019 | 2.982M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
2.982M
Minimum
Sep 2019
59.13M
Maximum
Jun 2023
29.29M
Average
30.71M
Median
Research and Development Expense (Quarterly) Benchmarks
| Rocket Pharmaceuticals Inc | 41.74M |
| Solid Biosciences Inc | 15.45M |
| Avidity Biosciences Inc | 52.82M |
| Sana Biotechnology Inc | 69.84M |
| Tenaya Therapeutics Inc | 22.86M |